TFG Asset Management’s Freeline Therapeutics Holdings FRLN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
– Sell
-266,666
Closed -$1.15M – 36
2023
Q3
$1.15M Hold
266,666
– – 0.21% 33
2023
Q2
$688K Sell
266,666
-1
-0% -$4 0.09% 40
2023
Q1
$1.82M Hold
266,667
– – 0.24% 36
2022
Q4
$1.9M Hold
266,667
– – 0.27% 35
2022
Q3
$2.8M Buy
266,667
+15,966
+6% +$208K 0.34% 44
2022
Q2
$3.27M Buy
250,701
+4,034
+2% +$51.9K 0.22% 89
2022
Q1
$4.14M Buy
246,667
+145,143
+143% +$2.69M 0.19% 99
2021
Q4
$3.02M Buy
101,524
+28,191
+38% +$1.15M 0.18% 104
2021
Q3
$3.75M Buy
73,333
+23,333
+47% +$1.66M 0.23% 81
2021
Q2
$6.11M Hold
50,000
– – 0.33% 56
2021
Q1
$9.22M Hold
50,000
– – 0.66% 27
2020
Q4
$13.7M Buy
50,000
+1,333
+3% +$335K 0.92% 20
2020
Q3
$11.4M Buy
+48,667
New +$12.2M 1.05% 24

Other funds holding FRLN

TFG Asset Management's FRLN Position: Q4 2023 in Review

TFG Asset Management sold out of Freeline Therapeutics Holdings (FRLN) in Q4 2023, closing a stake of 266,666 shares — an estimated $1.15M sold.

TFG Asset Management first reported a position in FRLN in Q3 2020 and held it in 13 quarters. The position peaked at $13.7M in Q4 2020. 15 funds tracked by Wall St. Rank hold FRLN as of Q4 2023.

  • TFG Asset Management reported no remaining Freeline Therapeutics Holdings position as of Q4 2023 after selling out during the quarter.
  • TFG Asset Management sold 266,666 Freeline Therapeutics Holdings shares in Q4 2023, an estimated $1.15M.
  • TFG Asset Management first reported a position in Freeline Therapeutics Holdings in Q3 2020 and held it in 13 quarters.
  • TFG Asset Management's Freeline Therapeutics Holdings position peaked at $13.7M in Q4 2020.
  • 15 funds tracked by Wall St. Rank held Freeline Therapeutics Holdings as of Q4 2023.

Based on TFG Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.